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Background: SPARC is a matricellular glycoprotein with growth-inhibitory and antiangiogenic activity in some cell
types. The study of this protein in hematopoietic malignancies led to conflicting reports about its role as a tumor
suppressor or promoter, depending on its different functions in the tumor microenvironment. In this study we
investigated the variations in SPARC production by peripheral blood cells from chronic myeloid leukemia (CML)
patients at diagnosis and after treatment and we identified the subpopulation of cells that are the prevalent source
of SPARC.
Methods: We evaluated SPARC expression using real-time PCR and western blotting. SPARC serum levels were
detected by ELISA assay. Finally we analyzed the interaction between exogenous SPARC and imatinib (IM), in vitro,
using ATP-lite and cell cycle analysis.
Results: Our study shows that the CML cells of patients at diagnosis have a low mRNA and protein expression of
SPARC. Low serum levels of this protein are also recorded in CML patients at diagnosis. However, after IM treatment
we observed an increase of SPARC mRNA, protein, and serum level in the peripheral blood of these patients that
had already started at 3 months and was maintained for at least the 18 months of observation. This SPARC increase
was predominantly due to monocyte production. In addition, exogenous SPARC protein reduced the growth of
K562 cell line and synergized in vitro with IM by inhibiting cell cycle progression from G1 to S phase.
Conclusion: Our results suggest that low endogenous SPARC expression is a constant feature of BCR/ABL positive
cells and that IM treatment induces SPARC overproduction by normal cells. This exogenous SPARC may inhibit CML
cell proliferation and may synergize with IM activity against CML.
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CML is a myeloproliferative disease caused by the t
(9;22) translocation [1] that generates BCR-ABL, a con-
stitutively active tyrosine kinase (TK). IM, a TK inhibitor
(TKI), is the elective drug for CML treatment. CML
patients in the chronic phase treated with IM achieve
deep and durable responses [2]. However, a small per-
centage of these patients and most advanced-phase
patients develop resistance to TKI therapy [3,4].* Correspondence: d.tibullo@unict.it
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reproduction in any medium, provided the orSecreted protein, acidic and rich in cysteine (SPARC) is
a multifunctional matricellular glycoprotein, also known
as osteonectin or BM-40. This protein has counter-
adhesive properties, has effects on cell shape, immune sur-
veillance and angiogenesis [5]; inhibits cell proliferation
and delays cell cycle in the G1 phase [6]. SPARC seems to
inhibit cell proliferation after digestion by MMP-3 [7] and
links with cell-surface receptors to activate G-protein
coupled signaling [8]. SPARC binds VEGF, preventing
VEGF-induced tyrosine phosphorylation of VEGFR1 and
antagonizing its pro-angiogenic effects [9]. The protein
also binds PDGF-B, blocking the binding to its receptors
and the proliferation signaling [10].ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 SPARC is underexpressed in CML patients at
diagnosis. Expression of SPARC was analyzed in PBMCs of 20
HC vs 40 CML patients by qRT-PCR. DATA are expressed as
means ± S.D.
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gression seems to depend on its different functions in
the tumor microenvironment. In some types of cancer,
SPARC correlates with poor prognosis (melanoma, gli-
oma, prostate and breast cancer), while in others the
protein functions as a tumor suppressor (ovarian and
colorectal cancers) [11]. In hematological diseases,
SPARC has been evaluated on MDS 5q-syndrome and
acute myeloid leukemia (AML) with MLL rearrange-
ments. In 5q-MDS, the deletion of SPARC is associated
with the pathogenesis of disease and patients responsive
to lenalidomide show an increase of SPARC expression
[12]. SPARC is transcriptionally silenced in AML with
rearrangement of the MLL (Mixed lineage leukemia)
gene and may function as a tumor suppressor in this
subset of patients. SPARC silencing is associated with
promoter methylation in MLL cell lines but not in
patients’ cells and the addition of exogenous purified
protein inhibits cell line proliferation [13]. In contrast,
the SPARC gene was up-regulated in multiple myeloma
and plasmacytoma [14]. A recently published study
reported that in CML, SPARC accumulates in TKI-
resistant CML cell lines. It activates the Fyn/ERK kinase
signaling that inhibits apoptosis and promotes IM resist-
ance [15]. In contrast to this work, Li and co-workers
[16] showed that transfection of K562 with the SATB1
plasmid induces SPARC over-expression, resulting in a
reduction of cell proliferation.
In this study we investigated the variations in SPARC
production by peripheral blood cells from CML patients
at diagnosis and after treatment and we identified the
subpopulation of cells that are the prevalent source of
SPARC.
Results
SPARC is downregulated in CML cells
SPARC mRNA and protein in CML cells from patients
at diagnosis was downregulated with respect to healthy
controls (HC) (p<0.001 for mRNA and p<0.05 for pro-
tein) (Figures 1 and 2b). Twenty-two patients were eval-
uated during TKI treatment: IM, NI (Nilotinib) or
alternating IM and NI every three months. In all TKI
treated patients a significant increase of SPARC mRNA
expression was recorded at 3 months of treatment and
this increase was maintained at 18 months of therapy
(p<0.01) (Figure 2a). A similar increase of the SPARC
protein level was observed in the peripheral blood cells
of three analyzed patients (p<0.001) during IM treat-
ment (Figure 2b). Interestingly, in one patient, discon-
tinuation of IM at the 12th month, resulted in a
significant decrease of the SPARC protein level that
increased again after IM was restarted (Figure 2c).
We also measured SPARC level in BCR/ABL positive
cell lines (K652, LAMA84) and in HL60, a BCR/ABLnegative acute myeloid leukemia cell line (Figure 3). The
protein appears to be downregulated only in chronic mye-
loid leukemia cell lines while no difference of SPARC
expression was observed in HL60 in respect to HC.
IM increases SPARC levels in the sera of patients
We also evaluated the secreted form of SPARC in 10
CML patients at diagnosis and in 6 of them at 6, 12, and
18 months during IM treatment by ELISA. We found
that SPARC serum levels were decreased at diagnosis
compared to HC (p<0.01) but then increased progres-
sively, achieving normal levels at 18 months (p<0.001)
(Figure 4).
In lymphoid cells, monocytes and granulocytes from CML
patients, SPARC was downregulated at diagnosis but
increased during IM therapy
In order to test which cell population predominantly
expresses SPARC mRNA, we separated PBMCs of 4 HC
and 4 CML patients, the latter at diagnosis and after
3 months of IM therapy. After magnetic separation of
lymphoid cells (CD3+ and CD19+), granulocytes (CD66b+)
and monocytes (CD14+), we tested the expression of
SPARC mRNA in each of these subsets. As shown in
Figure 5a, SPARC was predominantly expressed in
monocytes with respect to the total number of separated
cells both in HC and in CML patients. In the analyzed
cell subsets there was a similar distribution of SPARC
expression for HC and treated patients groups while in
CML patients at diagnosis an increase of granulocytes
expressing SPARC was observed at the expense of
monocytes. SPARC mRNA expression was calculated in
each sub-population of patients at diagnosis and after
3 months of IM treatment and compared with the
correspondent subsets of HC (Figure 5b). After IM
treatment, all 4 studied patients were in complete
Figure 2 SPARC expression increased during TKIs therapy. (a) Expression of SPARC was performed by qRT-PCR in PBMCs of 12 CML patients
at diagnosis (D) and during TKIs treatment; D vs 12 M: p<0.002. White circles: IM-treated patients; black squares: NI-treated patients; gray triangles:
alternating NI/IM treated patients. Results are expressed with respect to HC. (b) Analysis of SPARC expression in PBMCs of 3 CML patients (pt) at
D and during IM therapy by western blotting. The optical density of the bands was measured using Scion Image software. Results represent the
mean of three indipendent experiments; error bars denote S.D. (c) Protein levels decreased after interruption of IM therapy (12 M) and increased
after IM was restarted (24 M). Results represent the mean of three indipendent experiments; error bars denote S.D.
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BCR/ABL transcript.
SPARC expression in every cell population of CML
patients at diagnosis was lower than HC (lymphoid cells:
12 fold; monocytes: 9 fold; granulocytes: 2 fold), while
after 3 months of IM treatment an increase of SPARC
mRNA was found in all cell sub-populations (lymphoid
cells: 6 fold; monocytes: 16 fold; granulocytes: 57 fold
compared to HC cell subsets), (diagnosis vs treatment:Figure 3 Quantitative real time RT-PCR analysis of SPARC
expression in myeloid leukemia cell lines. Bars represent the
mean and standard deviation of three independent experiment.
SPARC resulted significantly down-regulated in BCR/ABL positive cell
lines only. K562 and LAMA84 vs HC: p<0.01; LAMA84-R vs
HC: p<0.05.p<0.01 in lymphoid cells and monocytes; p<0.001 in
granulocytes).
These results confirm that granulocytes from CML
patients at diagnosis express low levels of SPARC mRNA
and they also suggest that the percentage of normal cells
that express SPARC mRNA was lower than HC, thus
justifying our finding of low SPARC levels in CML
PBMC at diagnosis. On the contrary, distribution of
SPARC expression in normal cell populations exceeded
that of HC during IM treatment, indicating that theFigure 4 Levels of secreted SPARC increased during IM
therapy. Secreted protein was evaluated by ELISA in CML 10
patients at D, 6 of which followed during TKI therapy. Data are
expressed as means ± S.D.
Figure 5 SPARC mRNA expression by qRT-PCR in cell subsets after magnetic separation tecnology. a. Distribution of SPARC expression in
PBMCs of 4 HD and 4 CML patients at D and after 3 M of IM therapy calculated as percentage of expressing SPARC granulocytes, monocytes and
lymphocytes in respect to the total number of separated expressing SPARC cells. Data are expressed as means ± S.D. b. SPARC mRNA levels in
cell subsets of CML patients at D and after 3 M of therapy compared with the same cell populations of HC (calculated value of 2^-ΔΔCt in HD’
subsets was 1). Data are expressed as means ± S.D.
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PBMC during IM treatment is mainly due to normal
cells and in particular to normal monocytes.
In conclusion, the observed increase in SPARC expres-
sion after IM therapy is due to increased production by
non-neoplastic cells such as lymphocytes, monocytes
and granulocytes. The last population showed the high-
est increase but it should be underlined that they are
actually two different populations since at diagnosis
most granulocytes belong to the neoplastic clone while
at 3 months most granulocytes are normal.
SPARC inhibits the growth of K562 cell line
SPARC has been shown to induce growth arrest and
apoptosis in a number of different cell lines [13,17]. We
hypothesized that K562 and LAMA84 cells might also
be sensitive to these SPARC effects. To prove this hy-
pothesis, we first investigated whether SPARC increase
during therapy might contribute to TKIs cytotoxicity.
K562 cells were treated with serum before and after IM
therapy (6 months) of 6 different patients. In all condi-
tions with serum during therapy, K562 showed amortality between 25-31±9% in respect to the same sam-
ple at diagnosis. Anyhow SPARC antibody didn’t induce
any change in our results. Therefore, in these experi-
ments, the activity of IM is not mediated by circulating
SPARC. Second, we exposed cells to human recombin-
ant SPARC 2 days before exposure to IM, so that the
protein was efficiently internalized in the cells. After
72 h we evaluated cell proliferation and cell cycle pro-
gression. SPARC alone and IM alone induced a reduced
survival rate of 18±3.2% and 29±1.6% respectively vs un-
treated cells; their association led to a reduced cell via-
bility of 37.5±3.7% (Figure 6). After 96 h of incubation
the effect of the combination SPARC/IM was more evi-
dent since it induced a reduction of viability that was
16.5±3% higher than that induced by IM alone (p<0.01).
We next evaluated cell cycle induced modifications
and, as expected, IM inhibition of BCR/ABL tyrosine
kinase activity resulted in a G1 cell cycle arrest
[15,18,19]. Flow cytometry revealed an accumulation of
K562 cells in G0/G1 24 h after IM exposure (15±1.7%
more than untreated cells; p<0.01) (Figure 7a). Recom-
binant SPARC alone also induced the same block of the
Figure 6 The graph is representative for K562 cell line. Cell survival after exposure to IM, SPARC or their combination is showed. Cells were
pre-treated with SPARC followed by IM for 24 h. Percentage of viable cells was measured by ATP.lite at 24 h and 48 h after addition of IM. Results
represent the means of five independent experiments; error bars denote S.D.
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and the combination SPARC/IM showed an additive
effect (26.5±3.3% more than untreated cells; p<0.001).
This cell cycle arrest was not recorded after 48 h of IM
exposure while at this time point an increase of apop-
tosis was observed both in IM and SPARC/IM condi-
tions (respectively of 16±4% and 16.5±3.7% vs untreated
cells; p<0.01), but not with SPARC alone (Figure 7b).
Similar data were obtained in LAMA84-S cell line. Onb
a
Figure 7 Effect of IM, SPARC and their combination on the G0/G1 pha
at 24 (a) and 48 h (b) after cell exposure to IM. Analysis was performed by
experiments; error bars denote S.D.the contrary, LAMA 84-R, resistant to IM by mechan-
ism of gene amplification, did not show any cell cycle ar-
rest after exposure to exogenous SPARC. Therefore, the
recombinant protein did not sensitize LAMA84-R to IM
both at 24 and 48 hs of SPARC and TKI combination
exposure (data not shown).
In addition we analyzed effect of exogenous SPARC on
HL60 cells line to examine if recombinant protein leads
to a cell cycle arrest as in BCR/ABL positive cellsse and apoptosis in K562 cells. Cell cycle distribution were assessed
the ModFit program. Results represent the means of five indipendent
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concentration (15 μg/ml) used in K562 and in LAMA84
cell lines. As assumed by real time PCR data, the protein
did not induce any variation in cell cycle of HL60 in
comparison to untreated cells (data not shown).
These results suggest that exogenous SPARC is not
able to induce apoptosis in CML cells but it inhibits pro-
gression from the G1 to S phase in K562 and LAMA84
sensible to IM and its combination with IM potentiates
the TKI effect on the cell cycle.
Discussion
In this paper we show that CML cells have a low level of
SPARC and there is also a reduction of the secreted
form of SPARC in the serum of CML patients. Once
treatment with IM was initiated, we observed an in-
crease of SPARC mRNA and protein in the PBMCs,
reaching levels that are much higher than normal con-
trols. This increase was evident already at 3 months and
was maintained at least for the 18 months of observa-
tion. Accordingly, the concentration of SPARC in the
serum showed a progressive increase during IM treat-
ment and reached normal values at 18 months. In fact,
IM is a very effective treatment for CML. At 3 months,
most patients are in complete hematological response
and at 12 months most of them are in complete cyto-
genetic or even molecular response. In these conditions,
CML cells are virtually absent in the PBMCs of CML
patients and, however, the contribution of these cells to
the PBMC composition is negligible. Therefore, the mea-
sured SPARC mRNA after 3 months of treatment and
throughout the subsequent evaluations was produced by
normal cells, i.e. lymphoid cells, monocytes and non-
clonal granulocytes. This production is probably favored
by IM since we observed that, in one patient, discon-
tinuation of IM therapy resulted in a reduction of the
SPARC level while it rose again after restarting treat-
ment. The only two patients treated with an alternation
of IM and NI, showed the same pattern as patients trea-
ted with IM alone, thus favoring the hypothesis that the
increase of SPARC is a common phenomenon after any
TKI treatment.
We show that SPARC is mainly expressed by mono-
cytes with respect to the total number of analyzed cells
but, during IM treatment, other cell populations such as
normal lymphocytes and granulocytes increase their
SPARC production.
We also demonstrated that SPARC may synergize
in vitro with IM by blocking the cell cycle of CML cells
in the G0/G1 phase. We therefore hypothesize that the
increased production of SPARC by normal cells may
contribute to the efficacy of IM in reducing CML clone.
In this perspective, studies are ongoing in our lab in
order to evaluate if the levels of SPARC that can beachieved after treatment may be correlated with the
magnitude of the response to IM.
The study of SPARC in hematopoietic malignancies
led to conflicting reports about its role as a tumor sup-
pressor or promoter. A study by Li et al. supports an
anti-proliferative effect of SPARC on leukemic cells. The
authors reported that transfection of K562 cells with
SATB1 plasmid induced SPARC over-expression, result-
ing in a reduction of cell proliferation [16]. In contrast, a
recent study [15] reports intracellular SPARC as a
potential cause of resistance to IM in CML cells. How-
ever, the same authors pointed out that the cellular
localization of SPARC could be determinant in predict-
ing its activity. The discrepancy that exists in the litera-
ture on the activity of SPARC on different diseases is
probably linked to the fact that there are different
sources and different isoforms and even in the same dis-
ease SPARC may have different activities. In addition,
the activity of SPARC may depend on whether it is
secreted and associated with the extracellular matrix or
retained inside the cell. In this perspective, if the intra-
cellular form of SPARC may protect CML cells from IM
induced cell death [15], its secreted form could even be
toxic for the CML cells as it has been demonstrated not
only by our experiments but also for some subtypes of
acute myeloid leukaemia [13].
Initial studies showed that SPARC is important in
bone mineralization [20]. In this perspective, we [21]
and others [22-25] have demonstrated that in CML
patients treated with IM there is a transient increase in
bone-formation markers that could be linked to inhib-
ition of PDGFR signaling. We have also demonstrated
that also NI induced osteoblastogenesis in vitro, prob-
ably triggering the same IM targets [26]. Therefore the
increase of SPARC induced by TKIs could be related to
the well documented modification of the bone metabol-
ism observed in IM treated patients.
In CML cells, the BCR/ABL oncoprotein has prolifera-
tive effects activating the Ras/Raf/MEK/ERK, JAK/STAT
and PI3K/Akt pathways [27-30]. The autophosphoryla-
tion site Y177 on BCR/ABL binds the scaffolding
adaptor protein Gab2 [28] that activate both PI3K/Akt
and Raf/MEK/ERK pathways [27]. Inhibition of BCR/
ABL by IM results in a G1 cell cycle arrest mediated by
the PI3K pathway [31]. One method that is showing suc-
cess against IM-resistant CML cells is the treatment with
inhibitors that target Ras or PI3K [32]. Because SPARC
affects multiple downstream signaling pathways, such as
PI3K/AKT [11], in our study we focused on its potential
role as a tumor suppressor protein in CML cells. Many
studies have focused on the role of the protein in
tumorigenesis, but few on its potential role in modulat-
ing therapy sensitivity [33]. Here, we demonstrate that
exogenous exposure to SPARC in K562 cells induced a
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cells and appeared to confer an increased sensitivity of
K562 cells to IM. In addition, residual leukemia stem
and progenitor cells persist in IM-responsive patients
and may be a potential source of relapse. While integrins
such as very late antigen-4 and the adhesion molecule
CD44 have been demonstrated to be crucial for the per-
sistence of leukemic progenitors in the bone marrow
[34], SPARC is an anti-adhesive molecule and modulates
the cell matrix [35]; its down-regulation may increase
the adhesion of the hematopoietic stem cells to the sup-
porting stromal cells and provide a clonal advantage
[36]. Therefore the SPARC/TKI association could serve
to enhance the TKI effect on leukemic stem cells that
are not eliminated by BCR/ABL inhibitors [37-39].
On the basis of 1) our demonstration that in vitro
SPARC has an anti-proliferative effect on BCR/ABL
positive cells and influences the sensitivity of leukemic
cells to therapy and 2) the putative modulation of the
tumor microenviroment by this protein, it is conceivable
that the effects of exogenous SPARC could be exploited
therapeutically by using recombinant SPARC or one of
its derivate peptides. This possible approach is supported
by experiments on xenograft tumor models where intra-
peritoneal or subcutaneous injections of SPARC inhib-
ited tumor growth [33,40].Conclusion
Our data demonstrate that endogenous SPARC is
reduced in CML cells but IM treatment induces an
increased production of exogenous SPARC by normal
cells, mainly monocytes; since this protein has an anti-
proliferative effect, it may even contribute to the activity
of IM on leukemic cells.Methods
RNA extraction and qRT-PCR
Peripheral blood mononuclear cells (PBMCs) of patients
at diagnosis and during TKI treatment were obtained
using a Ficoll-Hypaque gradient. We analyzed 40 CML
patients at diagnosis, and for 22 of them we also col-
lected samples during first-line treatment with IM (18
patients), nilotinib (2 patients) or alternating treatment
with nilotinib and IM every three months (2 patients).
All enrolled patients signed an informed consent form
and all were followed with a monthly CBC count, mo-
lecular evaluation of the BCR/ABL transcript every
3 months, and cytogenetic evaluation every 6 months,
according to ELN guidelines.
RNA was extracted by Trizol reagent (Invitrogen,
Carlsbad, CA, USA). First strand cDNA was then
synthesized with Applied Biosystem (Foster City, CA,
USA) reverse transcription reagent [41].SPARC mRNA expression was assessed by TaqMan
Gene Expression, Applied Biosystem and quantified
using a fluorescence-based real-time detection method
by LightCycler (Roche Diagnostic Corp., Indianapolis,
IN, USA). For each patient, the relative expression level
of SPARC mRNA was normalized using ABL as an
invariant control.
Western blot analysis
Western Blot Analysis was performed according to the
manufacturer’s recommendations [42]. The antibody
directed against the human SPARC was obtained from
Haematological Thecnologies. An anti-mouse antibody
against actin (Sigma, St. Louis, MO, USA) was used to
assess equal loading. The blots were scanned, and the
optical density of the bands was measured using Scion
Image software (New York, NY).
ELISA assay
By using a specific enzyme-linked immunosorbent assay
(ELISA) test (R&D Systems, Abingdon, United Kingdom),
we evaluated SPARC levels in the serum of patients both
at diagnosis and at different time points during treatment
with IM. Ten healthy volunteers were used as control.
Lymphoid cell, granulocyte and monocyte separation
Purification of lymphoid cells (CD3+ and CD19+), granu-
locytes (CD66b+) and monocytes (CD14+) from PBMCs
was performed by a positive selection of these cells using
a magnetic separation kit (EasySep, STEMCELL Tech-
nologies, Vancouver, BC, Canada). Cell purity was deter-
mined by flow cytometry and was >95% for each cell
population.
Cells and culture conditions
K562, LAMA84 and LAMA84-R (resistant to IM) cell
line were cultured at 37°C in 5% CO2 in RPMI-1640
(CELBIO) with 10% FBS (Fetal Bovine Serum) and 1%
penicillin-streptomycin. For HL60 cells we used DMEM
(CELBIO) with 20% FBS and 1% penicillin-streptomycin.
In vitro SPARC treatment was performed by adding
15 μg/ml exogenous SPARC (R&D system) for 48 h fol-
lowed by 24 h of IM (Novartis Farma Spa, Origgio, Italy)
1 μM. Vitality and cell cycle distribution were assessed
at 24 and 48 h after cell exposure to IM.
ATP-lite1step assay for cell survival
The viability of cells was evaluated by the ATP-lite1step
assay (PerkinElmer, Monza, Italy). Luminescence was
measured using a Victor3 reader (Perkin Elmer).
Cell survival was calculated as the percentage of viable
cells in the treated suspension culture compared to the
untreated one.
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Cells were washed and resuspended in cold 80% ethanol
to a final concentration of 0.5 × 106 cells/ml for 1 h at 4°C.
The ethanol-fixed cells were centrifuged to remove ethanol
and the pellet was resuspended in propidium iodide stain-
ing reagent (0.1% triton X-100, 0.1 mM EDTA, 0.05 mg/ml
RNase A and 50 μg/ml propidium iodide). Cells were
stored in the dark at room temperature for about 3 h. Cells
were then analyzed with a flow cytometer (FC500 Beck-
man coulter; Beckman Coulter S.p.a., Milan, Italy) and pro-
cessed by the ModFit program.
Statistical analysis
The data are expressed as mean ± SD. Statistical analysis
was carried out by paired Student’s t-test or ANOVA
test. A p value <0.05 was considered to indicate a statis-
tically significant difference between experimental and
control groups.
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